DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Immune Checkpoint Inhibitors: Clinical Trial Tracker" clinical trials to their offering.
Oncology market, for decades, has been pillared on three areas: Surgery, Radiation Therapy and Chemotherapy. Immuno-oncology, especially immune checkpoint inhibitors, has recently gained traction from several stakeholders. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells.
Yervoy (an anti CTLA-4 inhibitor) was the first immune checkpoint inhibitor that was made commercially available in 2011 for treatment of patients suffering from unresectable or metastatic melanoma; it has enjoyed considerable success so far with annual sales of over USD 1 billion. The drug is currently being mirrored by various other drugs such as Opdivo, Keytruda, Empliciti and Tecentriq in clinical development.
The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform.The field has been abuzz with partnering activities; such collaborations provide a synergistic boom to both the partners in terms of enrichment of product portfolio, revenues and stability. Most common forms of partnerships include clinical trial collaborations, product licensing agreements, acquisitions and research collaborations.
In addition to the marketed drugs, we expect a number of drugs currently in advanced stages of development to achieve blockbuster status in the near future. The anticipated success of immune checkpoint inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants.
Key Topics Covered:
1. Market Overview
2. Dashboard: Pipeline and Trial Analysis
3. CTLA-4 Inhibitors: Trial Details
4. PD-1 Inhibitors: Trial Details
5. PDL-1 Inhibitors: Trial Details
6. Novel Immune Checkpoint Inhibitors: Trial Details
7. Molecules in Preclinical Development
8. Inclusion / Exclusion Criteria
9. Drivers and Restraints
10. Market Forecast: Assumptions
11. Market Forecast, 2016-2025
Companies Mentioned - Partial List
- Aarhus University Hospital
- Abbott
- AbbVie
- Academic and Community Cancer Research United
- Acerta Pharma BV
- Acetylon Pharmaceuticals
- ACT Oncology
- Adknoma Health Research
- AduroBioTech
- Advaxis
- Affimed
- Agenus
- AgonOx
- AHS Cancer Control Alberta
- AIO-Studien-gGmbH
- Alden Cancer Therapy II
- Alliance Foundation Trials
- Alligator Bioscience
- Altor Bioscience
- Ambrx
- American Association for Cancer Research
- Amgen
- Amplimmune
- AnaptysBio
- Apexigen
- arGEN-X
- ARMO BioSciences
- Astex Pharmaceuticals
- AstraZeneca
- Aurigene
- Australasian Lung Cancer Trials Group
- Australia and New Zealand Melanoma Trials Group
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Avon Breast Cancer Foundation
For more information about this clinical trials visit http://www.researchandmarkets.com/research/7frq9k/immune_checkpoint
